The effect of a diet reduction in advanced glycation end products on metabolic markers in patients with chronic coronary artery disease and type 2 diabetes
Abstract
Chronic coronary artery disease (CAD) remains the leading cause of death worldwide. Its complex pathophysiology is influenced by multiple risk factors, with diabetes being one of the most significant. In recent years, advanced glycation end products (AGE) have gained attention as key markers of diabetes-related cardiovascular complications. Carboxymethyl-lysine (CML), a major product of oxidative modification of glycated proteins, is widely recognized as a biomarker of oxidative stress and long-term protein damage in aging, atherosclerosis, and diabetes. However, much contradictory information regarding the low-AGE diet and its precise clinical implications remains incompletely understood.
To evaluate the impact of a low-AGE diet on plasma CML concentration and glucose and lipid profiles in patients with chronic coronary artery disease (CAD) and type 2 diabetes.
A randomized controlled trial was conducted in patients with type 2 diabetes (glucose level ≥126 mg/dL) and chronic coronary artery disease (CAD) over 15 days. Participants were randomly assigned to either a control group following their usual diet or an intervention group adhering to a low-AGE diet. Carboxymethyl-lysine (CML), triglycerides, total cholesterol, HDL-C, LDL-C, glucose, and insulin plasma concentration were measured at baseline and after 15 days of dietary intervention.
36 participants were included, of which 17 were allocated to the low-AGE diet group. The mean age was 60±3 years. At 15 days of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 36 participants or records.
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.